Abstract 3585: Second primary tumors after breast cancer: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) study

Author(s):  
Fulvio Ricceri ◽  
Carlotta Sacerdote ◽  
Rossana Critelli ◽  
Paolo Vineis ◽  
Elio Riboli
2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11539-e11539
Author(s):  
Gul Atalay Basaran ◽  
Aziz Yazar ◽  
Cihan Uras ◽  
Evrim Tezcanli ◽  
Devrim Cabuk ◽  
...  

e11539 Background: We aimed to investigate the clinical and pathologic characteristics of patients with breast cancer (BC) who had a non-breast primary tumor and treated in our hospital. Methods: We identified BC patients with a second non-breast primary tumor retrospectively in our database. The tumors arising in a sequence by less than 2 months are accepted as synchronous malignancies. We noted clinical and pathological characteristics of breast tumors and analyzed the relapse patterns, the frequency and type of second non-breast primary tumors. Results: A total of 48 patients were identified. Median age was 59 years old. Thirty-four patients were postmenopausal, 41 tumors were IDC, 2 were DCIS only, eight were multiffocal. Two patients had metastatic BC at the time of diagnosis. Ninety-three (n: 26) % patients had breast conserving surgery, 2 had bilateral BC. Twenty-eight patients had node negative disease, 12 had node positive disease and 2 had micrometatatic nodal involvement. Fifty-four % were T1, 31% were T2 tumors. Histological grade was 3 for 14, 2 for 15 and 1 for 7 breast tumors. Forty patients had ER positive disease, 4 had ER/ PR negative disease, 2 tumors were triple negative and 6 tumors were Her-2 positive. Among non-breast second primary tumors; 29 arose after, 11 arose before the diagnosis of BC and 8 arose synchronously with BC. The most common non-breast second primary tumors were as follows: 15% lung cancer, 20% colorectal cancers, 13% ovarian cancer, 10% thyroid cancer, and 8% lymphoma/leukemia. With a median follow up of 76 months, there were 6 relapses; 4 of them were BC relapses. Among these 4 BC relapses, 3 patients had brain metastases and one patient had bone metastasis. There were 4 deaths; 2 were due to BC metastases, one was due to rectal cancer metastasis and the other was due to relapse of sarcoma. Conclusions: Most breast tumors were at early stage and were hormone sensitive. The most common second non-breast primary tumors arising after diagnosis of BC were colorectal, thyroid and lung cancers. The most common second non-breast tumor arising synchronously with BC was lung cancer and the most common second non-breast tumor arising before diagnosis of BC was lymphoma/leukemia.


2006 ◽  
Vol 155 (6) ◽  
pp. 801-806 ◽  
Author(s):  
Robbert B T Verkooijen ◽  
Jan W A Smit ◽  
Johannes A Romijn ◽  
Marcel P M Stokkel

Objective: The aim of the present study is to assess the prevalence of second primary tumors in patients treated for thyroid cancer. Furthermore, we wanted to assess the standardized risk rates for all second primary tumors, but especially for breast cancer, as data in the literature indicate an excessive risk in differentiated thyroid cancer (DTC) patients for this tumor. Materials and methods: We included consecutive patients, who received ablation treatment with I-131 at the Leiden University Medical Center between January 1985 and December 1999 (n = 282). The mean period of follow-up was 10.6 ± 4.1 years. Results: Thirty-five of the 282 patients (12.4%) had a second primary tumor (SPT), either preceding or following the diagnosis of thyroid cancer. Five other patients had three primary tumors, including DTC. As a result, 40 additional tumors were found in this group, revealing an overall prevalence of 14.2%. Twenty tumors (7.1%) preceded the thyroid cancer with a mean interval of 5.7 years (range: 0.5–22.0 years), whereas 20 tumors (7.1%) occurred after this tumor with a mean interval of 6.7 years (range: 1.0–15.0 years). In 13 female patients, breast cancer was found as SPT. The standardized incidence rate (SIR) for all cancers after the diagnosis of DTC in this study population was not increased (1.13; confidence interval (CI): 0.68–1.69). However, we found an increased SIR of 2.26 (CI: 1.60–3.03) for all cancers either following or preceding DTC, which is mainly caused by a SIR of 3.95 (CI: 2.06–6.45) for breast cancer. Conclusion: Patients with DTC have an overall increased standardized incidence rate for second primary tumors, but not for second primary tumors following I-131 therapy. These findings suggest a common etiologic and/or genetic mechanism instead of a causal relation.


1997 ◽  
Vol 33 ◽  
pp. S150-S151
Author(s):  
G.P. Stathopoulos ◽  
N.A. Malamos ◽  
G.F. Samelis ◽  
P. Papakostas ◽  
A. Polychronis ◽  
...  

Head & Neck ◽  
2018 ◽  
Vol 41 (4) ◽  
pp. 1122-1130 ◽  
Author(s):  
Oisín Bugter ◽  
Steffi E. M. van de Ven ◽  
Jose A. Hardillo ◽  
Marco J. Bruno ◽  
Arjun D. Koch ◽  
...  

2019 ◽  
Vol 29 ◽  
pp. 64-70 ◽  
Author(s):  
Fausto Petrelli ◽  
Gianluca Tomasello ◽  
Sandro Barni ◽  
Antonio Varricchio ◽  
Antonio Costanzo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document